Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.

Pfizer's acquired products delivered $3.1 billion in Q1 revenue with 22% operational growth. Click here to read why I rate ...

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near ...

Pfizer's Schaeffer's Volatility Scorecard (SVS) comes in at 6 out of 100. In other words, shares have consistently realized ...

Pfizer is an innovative pharmaceutical giant that investors have given up on, which is an opportunity if you think long-term.

Pfizer (PFE) stock gained 0.5% premarket after Q1 EPS of $0.75 topped forecasts. Eliquis drove revenue strength as company ...

Pfizer (NYSE:PFE | PFE Price Prediction) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at ...

On May 14, Wolfe Research analyst Alexandria Hammond raised the firm’s price recommendation on Pfizer Inc. (NYSE:PFE) to $26 ...

During the coronavirus pandemic, investors got a little too excited about Pfizer's (NYSE: PFE) vaccine opportunity. When demand for COVID vaccines cooled off, the stock plunged. And it hasn't really ...